The dynamics of chronic gout treatment: medication gaps and return to therapy.

Meyers Primary Care Institute, Worcester, Mass., USA.
The American journal of medicine (Impact Factor: 5.3). 01/2010; 123(1):54-9. DOI: 10.1016/j.amjmed.2009.05.026
Source: PubMed

ABSTRACT To identify gaps in therapy with urate-lowering drugs for the treatment of gout as well as factors associated with resuming therapy.
From 2 integrated delivery systems, we identified patients 18 years or older with a diagnosis of gout who initiated use of a urate-lowering drug from January 1, 2000 through June 30, 2006 and who had a gap in therapy. A gap was defined as a period of over 60 days after the completion of 1 prescription in which no refill for a urate-lowering drug was obtained. Survival curves were used to assess return to therapy of urate-lowering drugs. Cox proportional hazards analysis estimated the association between covariates and return to therapy.
There were 4166 new users of urate-lowering drugs (97% received allopurinol), of whom 2929 (70%) had a gap in therapy. Among those with a gap, in 75% it occurred in the first year of therapy. Fifty percent of patients with a gap returned to therapy within 8 months, and by 4 years it was 75%. Age 45-74 years (<45 referent) and greater duration of urate-lowering drug use before the gap was associated with resuming treatment within 1 year. In contrast, receipt of nonsteroidal anti-inflammatory drugs or glucocorticoids in the year before the gap was associated with a reduced likelihood of resuming therapy.
The majority of gout patients with gaps in urate-lowering drug use returned to treatment. More investigation is needed to better understand why patients may go for months without refilling prescriptions, given the clinical consequences of nonadherence.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Gout care is suboptimal because of lack of translation of knowledge into real-world practice, despite evidence-based guidelines. We have developed processes to ensure systematic care for gout patients and determined the predictors for achievement of a target serum uric acid (SUA) concentration of < 360 μmol/L in a prospective cohort of Asian gout patients requiring allopurinol therapy. Methods: A 1-year clinical practice improvement project was undertaken using evidence-based guidelines and quality planning tools. Interventions included comprehensive patient education, enhanced telephone access, reappointments and refills, upward titration of allopurinol with no limitation specified by renal function, and increased frequency of visits until the target SUA concentration was achieved. The primary outcome was the time to achieve an SUA level of <360 μmol/L. Results: We recruited 126 gout patients. The median time to achieving the target SUA concentration was 36.9 weeks [95% confidence interval (CI) 29.3-44.4]. Based on survival analysis, the proportion of patients achieving the target was 8.1% (95% CI 3.2-13.0), 40.6% (95% CI 31.4-50.8), and 72.0% (95% CI 61.2-82.8) at 3, 6, and 12 months, respectively. On average, our patients who achieved the target were seen once every 2 months and achieved the target after a mean of 2.5 (SD = 1.1) visits. Frequency of follow-up visits and older patients not taking aspirin were independent predictors associated with achieving the target outcome, regardless of renal function. Conclusions: Optimization of control of SUA is achievable, even in the setting of renal impairment, by redesigning and implementing processes involving changes in physician prescribing habits, enhanced nursing interventions, and patient empowerment and education.
    Scandinavian journal of rheumatology 07/2012; 41(6). · 2.51 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Gout is crystal-induced arthritis with hyperuricemia. Uric acid lowering agent (UALA) is the maintenance drug of its treatment. Drug adherence is an important factor that influences treatment outcome. The purpose this study was to examine the drug adherence to UALA of 303 gouty patients and to analyze the factors associated with compliance.
    The Journal of the Korean Rheumatism Association 01/2010; 17(2).
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Recent data suggesting the growing problem of medication non-adherence in gout has called for the need to synthesize the burden, determinants, and impacts of the problem. Our objective was to a conduct a systematic review of the literature examining medication adherence among patients with gout in real-world settings. Methods: We conducted a search of Medline, Embase, International Pharmaceutical Abstracts, PsycINFO, and CINAHL databases and selected studies of gout patients and medication adherence in real-world settings. We extracted information on study design, sample size, length of follow-up, data source (e.g. prescription records vs. electronic monitoring vs. self-report), type of non-adherence problem evaluated, adherence measures and reported estimates, and determinants of adherence reported in multivariable analyses. Results: We included 16 studies, which we categorized according to methods used to measure adherence including electronic prescription records (10), clinical records (1), electronic monitoring devices (1), and self-report (4). The burden of non-adherence was reported in all studies and among studies based on electronic prescription records, adherence rates were all below 0.80 and the proportion of adherent patients ranged from 10% to 46%. Six studies reported on determinants, with older age and having comorbid hypertension consistently shown to be positively associated with better adherence. One study showed the impact of adherence on achieving serum uric acid target. Conclusions: With less than half of gout patients in real-world settings adherent with their treatment, this systematic review highlights the importance of discussing adherence with medications during health care professional encounters with patients. © 2014 American College of Rheumatology.
    Arthritis care & research. 04/2014;

Full-text (2 Sources)

Available from
Jun 1, 2014